FOR PATIENTS WITH RELAPSING FORMS OF MS

  • The efficacy of VUMERITY is based upon bioavailability studies in patients with relapsing forms of multiple sclerosis and healthy subjects comparing dimethyl fumarate to VUMERITY1
  • In Study 1 and Study 2 pivotal trials, dimethyl fumarate demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1

Coverage and Copay Program for eligible patients

Access and Reimbursement

Patient support on starting treatment and managing common side effects

Support Services

Distinct chemical structure from that of dimethyl fumarate but is converted to the same active metabolite

Bioequivalent Exposure

VUMERITY offers the established efficacy of dimethyl fumarate

Efficacy

VUMERITY offers the well-understood safety of dimethyl fumarate

Safety

There are many things to consider when helping your patients get started on therapy.